Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

Share Price is delayed by 15 minutes
Get Live Data
33.50    0.00 (0.00%)
Bid:
32.00
Ask:
35.00
Spread: 3.00 (9.375%)
Market Cap: £18.03m
COG Live PriceLast checked at - London Stock Exchange

Intraday Cambridge Cog Share Chart

Notice of Results

20 Aug 2015 07:00

RNS Number : 5413W
Cambridge Cognition Holdings PLC
20 August 2015
 

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Notice of Results

Investor Results Presentations

 

Cambridge Cognition Holdings plc (AIM: COG), which specialises in computerised neuropsychological tests including those enabling the early detection of dementia, will be reporting its interim results for the six months ended 30 June 2015 on Thursday 10 September 2015.

 

Analyst presentation

Steven Powell, Chief Operating Officer and Nick Walters, Chief Financial Officer will be hosting an analyst briefing on the day of results, Thursday 10 September 2015, at 9.30am at Walbrook PR, 4 Lombard Street, London, EC3V 9HD.

 

Investor results presentation

A briefing for all investors will take place on Monday 14 September 2015 at Rocket, 6 Adams Court, Old Broad Street, London, EC4N 1DX from 4.30pm for a 4.45pm start, and will be followed by drinks and canapés.

 

If you would like to register to attend either presentation, or require further information, please contact Lianne Cawthorne on +44(0)20 7933 8788 or email camcog@walbrookpr.com.

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Operating Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

 

 

 

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or camcog@walbrookpr.com

Lianne Cawthorne

Mob: 07584 391 303

Paul McManus

Mob: 07980 541 893

   

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products under the Cantab mobile brand, to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORBUGDICDBBGUC
Date   Source Headline
2nd Nov 20217:00 amRNSDirectorate Change
26th Oct 20217:00 amRNSContract for pivotal schizophrenia clinical trial
6th Oct 202110:06 amRNSHolding(s) in Company
21st Sep 20217:00 amRNSInterim Results
3rd Aug 20217:00 amRNSTrading Update and Notice of Results
9th Jul 20214:41 pmRNSSecond Price Monitoring Extn
9th Jul 20214:35 pmRNSPrice Monitoring Extension
9th Jul 20217:00 amRNS£1 million contract for late phase cancer trial
1st Jul 20217:00 amRNSSpin-out of Monument Therapeutics
28th Jun 20214:40 pmRNSSecond Price Monitoring Extn
28th Jun 20214:36 pmRNSPrice Monitoring Extension
28th Jun 20212:06 pmRNSSecond Price Monitoring Extn
28th Jun 20212:00 pmRNSPrice Monitoring Extension
28th Jun 202111:05 amRNSSecond Price Monitoring Extn
28th Jun 202111:00 amRNSPrice Monitoring Extension
28th Jun 20217:00 amRNSNew £2.2 million contract
14th Jun 20217:00 amRNS£1.4m of contracts for digital health & wearables
11th Jun 20217:00 amRNSBrain Health Registry Cognitive Assessment Partner
3rd Jun 20213:58 pmRNSHolding(s) in Company
2nd Jun 20217:00 amRNSAppointment of Executive Director
27th May 202112:58 pmRNSResult of AGM and Board Changes
5th May 20217:00 amRNSPosting of Annual Report & Notice of AGM
4th May 202111:52 amRNSGrant of Options
8th Apr 20214:40 pmRNSSecond Price Monitoring Extn
8th Apr 20214:36 pmRNSPrice Monitoring Extension
8th Apr 20212:06 pmRNSSecond Price Monitoring Extn
8th Apr 20212:00 pmRNSPrice Monitoring Extension
8th Apr 202111:05 amRNSSecond Price Monitoring Extn
8th Apr 202111:00 amRNSPrice Monitoring Extension
8th Apr 20217:00 amRNSNew £0.5m contract for cognitive at home testing
30th Mar 20217:00 amRNS£1.3 million contract for a schizophrenia trial
23rd Mar 20217:00 amRNSResults for the year ended 31 December 2020
11th Mar 20217:00 amRNSInvestor Presentation
17th Feb 20216:20 pmRNSHolding(s) in Company
19th Jan 20216:03 pmRNSHolding(s) in Company
19th Jan 202111:06 amRNSSecond Price Monitoring Extn
19th Jan 202111:00 amRNSPrice Monitoring Extension
19th Jan 20217:00 amRNSTrading Update, Board Change & Notice of Results
21st Dec 20207:00 amRNSNew digital health contract worth over £700,000
2nd Dec 20201:10 pmRNSHolding(s) in Company
2nd Nov 20202:55 pmRNSGrant of Options
7th Oct 20207:00 amRNSNew £750,000 digital health contract
5th Oct 20207:00 amRNSInvestor Presentation
22nd Sep 20207:00 amRNSInterim Results
21st Sep 20203:13 pmRNSHolding(s) in Company
14th Sep 20207:00 amRNSAppointment of Non-Executive Director
8th Sep 20209:57 amRNSNotice of Results
7th Sep 202012:19 pmRNSHolding(s) in Company
1st Sep 20207:00 amRNS£2m contract for three schizophrenia trials
27th Jul 20201:11 pmRNSResult of AGM and Board Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.